Study Title
iMATRIX: A Phase I/II, Open-Label, Multicenter, Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available
Protocol ID
iMATRIX (GO42286)
Condition/s
ALK Fusion-positive Solid or CNS Tumors
Diagnosis Stage
Relapse/refractory
Location
NSW, QLD, VIC, WA
Sponsor
Hoffmann-La Roche
Links
Trial Status
Open
Sites
Sydney Children's Hospital
The Royal Children's Hospital, Melbourne
Perth Children's Hospital
Queensland Children's Hospital
The Children's Hospital at Westmead
The Royal Children's Hospital, Melbourne
Perth Children's Hospital
Queensland Children's Hospital
The Children's Hospital at Westmead
Study Type
Treatment
Phase
Phase 1/2
Age Eligibility
up to 17 Years
International registry ID's
NCT04774718
| Study Title | iMATRIX: A Phase I/II Open-Label Multicenter Study Evaluating the Safety Pharmacokinetics and Efficacy of Alectinib in Pediatric Patients With ALK Fusion-Positive Solid or CNS Tumors for Whom Prior Treatment Has Proven to be Ineffective or for Whom There is No Satisfactory Treatment Available |
|---|---|
| Protocol ID | iMATRIX (GO42286) |
| Disease (Sub Disease) | ALK Fusion-positive Solid or CNS Tumors |
| Diagnosis Stage | Relapse/refractory |
| Location | NSW / QLD / VIC / WA |
| Sponsor | Hoffmann-La Roche |
| Links | https://clinicaltrials.gov/ct2/show/NCT04774718 |
| Trial Status | Open |
| Trial Open Date | 26/07/2021 |
| Sites | Sydney Children's Hospital / The Royal Children's Hospital, Melbourne/ Perth Children's Hospital/ Queensland Children's Hospital/ The Children's Hospital at Westmead / |
| Study Type | Treatment |
| Phase | Phase 1/2 |
| Age Eligibility | up to 17 Years |
| International registry ID's | NCT04774718 |